Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunogenicity and In Vivo Protective Effects of Recombinant Nucleocapsid-Based SARS-CoV-2 Vaccine Convacell®
Sevastyan O. Rabdano, Ellina Ruzanova, Iuliia V. Pletyukhina, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 874-874
Open Access | Times Cited: 11

Showing 11 citing articles:

Vaccine adjuvants for infectious disease in the clinic
Morgan Goetz, Naaz Thotathil, Zongmin Zhao, et al.
Bioengineering & Translational Medicine (2024) Vol. 9, Iss. 4
Open Access | Times Cited: 8
The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein
Noe Juvenal Mendoza-Ramírez, Julio García‐Cordero, Gaurav Shrivastava, et al.
Journal of Immunology Research (2024) Vol. 2024, pp. 1-18
Open Access | Times Cited: 5
Differential decline of SARS‐CoV‐2‐specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID‐19
Bernhard Kratzer, Pia Gattinger, Doris Trapin, et al.
Allergy (2024) Vol. 79, Iss. 9, pp. 2482-2501
Open Access | Times Cited: 5
N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial
Sevastyan O. Rabdano, Ellina Ruzanova, Anastasiya Evgenievna Vertyachikh, et al.
Journal of Infection (2024), pp. 106288-106288
Open Access | Times Cited: 5
Protective potential of structural proteins of the SARS-CoV-2 virus in protecting against COVID-19
Inna V. Dolzhikova, Daria M. Grousova, Ilya D. Zorkov, et al.
Journal of microbiology epidemiology immunobiology (2025) Vol. 101, Iss. 6, pp. 769-778
Open Access
Immunobiology of COVID-19: Mechanistic and therapeutic insights from animal models
Hong‐Yi Zheng, Tian‐Zhang Song, Yong‐Tang Zheng
动物学研究 (2024) Vol. 45, Iss. 4, pp. 747-766
Open Access | Times Cited: 4
Overview of Nucleocapsid-Targeting Vaccines against COVID-19
Alexandra Rak, Irina Isakova-Sivak, Larisa Rudenko
Vaccines (2023) Vol. 11, Iss. 12, pp. 1810-1810
Open Access | Times Cited: 10
Safety and Immunogenicity of the Convacell® Recombinant N Protein COVID-19 Vaccine
Sevastyan O. Rabdano, Ellina Ruzanova, Denis Makarov, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 100-100
Open Access | Times Cited: 2
Eco‐friendly materials for next‐generation vaccination: From concept to clinical reality
Neha Kaushik, Paritosh Patel, Ravi Gupta, et al.
SmartMat (2024) Vol. 5, Iss. 5
Open Access | Times Cited: 2
Impact of SARS-CoV-2 Vaccine and Infection History on Antiviral Immunity Post Breakthrough Infection
Carla Saade, Timothée Bruel, Lou-Léna Vrignaud, et al.
(2024)
Closed Access | Times Cited: 1
LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters
Warren R. J. de Moor, Anna‐Lise Williamson, Georgia Schäfer, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1409-1409
Open Access | Times Cited: 2
Page 1

Scroll to top